Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Socrates phase II study result...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).
Bibliographic Details
Main Authors:
Glynne-Jones, R
,
Sebag-Montefiore, D
,
Samuel, L
,
Falk, S
,
Maughan, T
,
McDonald, A
Format:
Conference item
Published:
2005
Holdings
Description
Similar Items
Staff View
Similar Items
Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).
by: Glynne-Jones, R, et al.
Published: (2004)
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
by: Sebag-Montefiore, D, et al.
Published: (2005)
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
by: Glynne-Jones, R, et al.
Published: (2007)
Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
by: Evans, T, et al.
Published: (2006)
Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
by: Anchuan Li, et al.
Published: (2022-07-01)